DMRT2: A Protein Implicated in Neurological Disorders (G10655)

Target Name: DMRT2

NCBI ID: G10655

DMRT2

DMRT2: A Protein Implicated in Neurological Disorders

DMRT2 (doublecortin) is a protein that is expressed in various tissues of the brain, including the prefrontal cortex, basal ganglia, and cerebellum. It is a member of the neurotrophic factor family, which includes proteins that are involved in the development, maintenance, and survival of neural stem cells and glial cells.

DMRT2 has been shown to play a role in the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. It has also been implicated in the development of neurodegenerative diseases, such as multiple sclerosis and amyotrophic lateral sclerosis.

One of the key functions of DMRT2 is its role in modulating the activity of neural stem cells. These cells are responsible for the development and maintenance of the nervous system, and they can give rise to a wide range of neural cells, including neurons and glial cells.

Studies have shown that DMRT2 can promote the self-renewal and survival of neural stem cells, and that it can also inhibit the differentiation of these cells into neurons or glial cells. This means that DMRT2 may be a useful target for drugs that are designed to treat neurodegenerative diseases.

Another function of DMRT2 is its role in modulating the activity of glial cells, which are a type of immune cell that support the healthy function of neurons. Studies have shown that DMRT2 can regulate the production and function of glial cells, and that it can also influence their ability to respond to harmful substances.

The prefrontal cortex is the frontmost part of the brain, and it is responsible for a wide range of cognitive functions, including decision-making, problem-solving, and working memory. Researchers have been interested in studying DMRT2 because of its potential role in the development and maintenance of these functions.

Studies have shown that DMRT2 is expressed in the prefrontal cortex, and that it is involved in the formation of neural circuits that are important for these functions. This suggests that DMRT2 may be a useful target for drugs that are designed to improve cognitive function in individuals with neurodegenerative diseases.

In conclusion, DMRT2 is a protein that is expressed in various tissues of the brain, and it has been implicated in the development and progression of a wide range of neurological disorders. It is also involved in the modulation of the activity of neural stem cells and glial cells, and it may be a useful target for drugs that are designed to treat these disorders. Further research is needed to fully understand the role of DMRT2 in the development and treatment of neurodegenerative diseases.

Protein Name: Doublesex And Mab-3 Related Transcription Factor 2

Functions: Transcriptional activator that directly regulates early activation of the myogenic determination gene MYF5 by binding in a sequence-specific manner to the early epaxial enhancer element of it. Involved in somitogenesis during embryogenesis and somite development and differentiation into sclerotome and dermomyotome. Required for the initiation and/or maintenance of proper organization of the sclerotome, dermomyotome and myotome (By similarity)

The "DMRT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DMRT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets